Table 1.
Baseline clinical and demographic variables of the subjects in the REDUCE study
| Variables Baseline clinical variables |
Placebo group | Drug group | ||||
|---|---|---|---|---|---|---|
|
|
|
|||||
| PCa (N=410) | Non-PCa (N=1244) | P | PCa(N=304) | Non-PCa(N=1281) | P | |
| Age | ||||||
| Mean(SD), year | 63.52(5.99) | 62.22(6.01) | 0.0001 | 63.88(5.87) | 62.78(5.97) | 0.0037 |
| Median(range), year | 63(50–76) | 62(49–76) | 64(51–75) | 63(49–75) | ||
| No.(%) with positive DRE | 20(5) | 47(4) | 0.33 | 12(4) | 55(4) | 0.78 |
| Prostate volume | ||||||
| Mean(SD), mL* | 44.2(21.4) | 46.76(16.13) | 0.03 | 40.27(1.47) | 44.93(1.44) | 3.63×10−6 |
| Median(range), mL | 41.61(9.01–257) | 45.46(3.66–127) | 40.69(12.46–108.4) | 45.62(11.97–257.17) | ||
| Total PSA levels | ||||||
| Mean(SD), ng/mL* | 5.78(1.37) | 5.52(1.4) | 0.01 | 5.77(1.4) | 5.55(1.39) | 0.058 |
| Median(range), ng/mL | 5.7(2.5–10.2) | 5.7(1.8–14.2) | 5.8(2–15.6) | 5.6(1.9–11.1) | ||
| PSA density(PSA/PV) | ||||||
| Mean(SD), ng/mL2* | 0.14(1.67) | 0.14(0.07) | 4.67×10−6 | 0.14(1.62) | 0.12(1.55) | 1.10×10−6 |
| Median(range), ng/mL2 | 0.14(0.02–0.63) | 0.12(0.03–0.58) | 0.14(0.04–0.56) | 0.12(0.02–0.61) | ||
| Free-to-total PSA ratio | ||||||
| Mean(SD) | 0.16(0.06) | 0.17(0.06) | 0.02 | 1.17(1.06) | 1.19(1.06) | 7.73×10−6 |
| Median(range) | 0.16(0.03–0.47) | 0.16(0.03–0.47) | 1.16(1.04–1.56) | 1.18(1.02–1.86) | ||
| No. of cores sampled at baseline biopsy | ||||||
| Mean(SD) | 8.21(2.27) | 8.58(2.39) | 0.004 | 8.08(2.19) | 8.65(2.40) | 0.0002 |
| Median(range) | 8(3–19) | 8(2–22) | 8(4–16) | 8(2–20) | ||
| No.(%) with positive family history | 68(17) | 146(12) | 0.01 | 48(16) | 176(14) | 0.36 |
*
P-value were analyzed after taking natural logarithm of the variables.
DRE: digital rectal exam; PCa: prostate cancer; PSA: prostate-specific antigen; PV: prostate volume; SD: standard deviation